Key Takeaway: Cognition Therapeutics is focusing on a significant form of dementia, although specific details about their approach or findings are not provided in the article. The article primarily consists of a disclaimer regarding third-party website content. As such, there is limited information available about the company's initiatives or developments.
Price reaction · baseline $0.7693 (2025-01-22 close) · hit pre-market · 1 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.